Sabine Mueller

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/4048735/publications.pdf

Version: 2024-02-01

		87888	88630
125	5,534	38	70
papers	citations	h-index	g-index

127	127	127	8021
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Repurposing Vandetanib plus Everolimus for the Treatment ofACVR1-Mutant Diffuse Intrinsic Pontine Glioma. Cancer Discovery, 2022, 12, 416-431.	9.4	25
2	Intracranial mesenchymal tumors with FETâ€CREB fusion are composed of at least two epigenetic subgroups distinct from meningioma and extracranial sarcomas. Brain Pathology, 2022, 32, e13037.	4.1	11
3	Imipridones affect tumor bioenergetics and promote cell lineage differentiation in diffuse midline gliomas. Neuro-Oncology, 2022, 24, 1438-1451.	1.2	36
4	Serial H3K27M cell-free tumor DNA (cf-tDNA) tracking predicts ONC201 treatment response and progression in diffuse midline glioma. Neuro-Oncology, 2022, 24, 1366-1374.	1.2	36
5	Neurologic complications in the treatment of childhood malignancies. , 2022, , 433-462.		0
6	DIPG-07. Preclinical and case study results underpinning the phase II clinical trial testing the combination of ONC201 and paxalisib for the treatment of patients with diffuse midline glioma (NCT05009992). Neuro-Oncology, 2022, 24, i18-i19.	1.2	0
7	RARE-13. Clinical management and functional and survival outcomes in pediatric craniopharyngioma, a patient and family perspective. Neuro-Oncology, 2022, 24, i12-i12.	1.2	0
8	LGG-52. Volumetry-based response characterization of recurrent pediatric low-grade gliomas in PNOC clinical Neuro-oncology trials. Neuro-Oncology, 2022, 24, i100-i100.	1.2	0
9	DIPG-31. Prognostic and predictive biomarkers of response in children and young adults with H3K27M-altered diffuse intrinsic pontine glioma: results from a multi-center, interventional clinical trial (PNOC003). Neuro-Oncology, 2022, 24, i25-i25.	1.2	0
10	NURS-02. Incorporating Nurses and Advanced Practice Providers into Clinical Trial Consortiums; results of a multi-institutional survey from the Pacific Pediatric Neuro-Oncology Consortium (PNOC). Neuro-Oncology, 2022, 24, i146-i146.	1.2	0
11	RARE-17. Multi-institutional craniopharyngioma cohort highlights need for more comprehensive data collection on comorbidities and quality of life. Neuro-Oncology, 2022, 24, i13-i13.	1.2	0
12	EPCT-08. Disease-specific working groups within the Pacific Pediatric Neuro-Oncology Consortium (PNOC) and Childrenâ€™s Brain Tumor Network (CBTN) facilitate multi-disciplinary collaboration and translation of innovative strategies in pediatric neuro-oncology. Neuro-Oncology, 2022, 24, i37-i37.	1.2	0
13	DIPG-47. TSO500ctDNA sequencing reveals oncogenic mutations and copy number variations in the liquid biome of children with diffuse midline glioma. Neuro-Oncology, 2022, 24, i29-i29.	1.2	0
14	Wee1 kinase inhibitor adavosertib with radiation in newly diagnosed diffuse intrinsic pontine glioma: A Childrenâ€™s Oncology Group phase I consortium study. Neuro-Oncology Advances, 2022, 4, .	0.7	2
15	Rate of radiation-induced microbleed formation on 7T MRI relates to cognitive impairment in young patients treated with radiation therapy for a brain tumor. Radiotherapy and Oncology, 2021, 154, 145-153.	0.6	11
16	Mechanisms of imipridones in targeting mitochondrial metabolism in cancer cells. Neuro-Oncology, 2021, 23, 542-556.	1.2	30
17	Optimal therapeutic targeting by HDAC inhibition in biopsy-derived treatment-naÃ¯ve diffuse midline glioma models. Neuro-Oncology, 2021, 23, 376-386.	1.2	43
18	Standardization of the liquid biopsy for pediatric diffuse midline glioma using ddPCR. Scientific Reports, 2021, 11, 5098.	3.3	31

#	Article	IF	Citations
19	Relationship between 7T MR-angiography features of vascular injury and cognitive decline in young brain tumor patients treated with radiation therapy. Journal of Neuro-Oncology, 2021, 153, 143-152.	2.9	3
20	Multiâ€institutional analysis of treatment modalities in basal ganglia and thalamic germinoma. Pediatric Blood and Cancer, 2021, 68, e29172.	1.5	3
21	EPCT-02. COMPARISON OF TARGETED AGENTS RECOMMENDED BY THE CNS-TAP TOOL TO THOSE SELECTED BY A TUMOR BOARD IN A MOLECULARLY-DRIVEN DIPG CLINICAL TRIAL. Neuro-Oncology, 2021, 23, i46-i46.	1.2	0
22	EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. Neuro-Oncology, 2021, 23, i6-i6.	1.2	0
23	Radiation in Combination With Targeted Agents and Immunotherapies for Pediatric Central Nervous System Tumors - Progress, Opportunities, and Challenges. Frontiers in Oncology, 2021, 11, 674596.	2.8	7
24	Topographic correlates of driver mutations and endogenous gene expression in pediatric diffuse midline gliomas and hemispheric high-grade gliomas. Scientific Reports, 2021, 11, 14377.	3.3	2
25	Diffuse hemispheric glioma, H3 G34-mutant: Genomic landscape of a new tumor entity and prospects for targeted therapy. Neuro-Oncology, 2021, 23, 1974-1976.	1.2	12
26	Pilot Study of Hyperpolarized ¹³C Metabolic Imaging in Pediatric Patients with Diffuse Intrinsic Pontine Glioma and Other CNS Cancers. American Journal of Neuroradiology, 2021, 42, 178-184.	2.4	18
27	Preclinical and clinical evaluation of German-sourced ONC201 for the treatment of H3K27M-mutant diffuse intrinsic pontine glioma. Neuro-Oncology Advances, 2021, 3, vdab169.	0.7	11
28	Neuro-Oncology Practice Clinical Debate: targeted therapy vs conventional chemotherapy in pediatric low-grade glioma. Neuro-Oncology Practice, 2020, 7, 4-10.	1.6	11
29	Stroke impact on mortality and psychologic morbidity within the Childhood Cancer Survivor Study. Cancer, 2020, 126, 1051-1059.	4.1	14
30	Advances in Targeted Therapies for Pediatric Brain Tumors. Current Treatment Options in Neurology, 2020, 22, 1.	1.8	16
31	Response to Letter by Walker et al. Neuro-Oncology Practice, 2020, 7, 574-575.	1.6	0
32	Opportunities for the treatment of NF1-associated low-grade gliomas: how to decide on the best treatment options for patients?. Neuro-Oncology, 2020, 22, 1415-1416.	1.2	1
33	Comprehensive analysis of diverse low-grade neuroepithelial tumors with FGFR1 alterations reveals a distinct molecular signature of rosette-forming glioneuronal tumor. Acta Neuropathologica Communications, 2020, 8, 151.	5.2	35
34	Diffuse midline glioma: review of epigenetics. Journal of Neuro-Oncology, 2020, 150, 27-34.	2.9	29
35	Response to Karajannis et al.. Neuro-Oncology Practice, 2020, 7, 571-571.	1.6	0
36	Response assessment in paediatric high-grade glioma: recommendations from the Response Assessment in Pediatric Neuro-Oncology (RAPNO) working group. Lancet Oncology, The, 2020, 21, e317-e329.	10.7	69

#	Article	IF	Citations
37	Neurocognitive Outcomes in Children with Brain Tumors. Seminars in Neurology, 2020, 40, 315-321.	1.4	15
38	Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. Scientific Reports, 2020, 10, 10954.	3.3	7
39	Pediatric hemispheric high-grade glioma: targeting the future. Cancer and Metastasis Reviews, 2020, 39, 245-260.	5.9	26
40	Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nature Medicine, 2020, 26, 712-719.	30.7	172
41	NFB-17. MEK INHIBITOR BINIMETINIB SHOWS CLINICAL ACTIVITY IN CHILDREN WITH NEUROFIBROMATOSIS TYPE 1- ASSOCIATED PLEXIFORM NEUROFIBROMAS: A REPORT FROM PNOC AND THE NF CLINICAL TRIALS CONSORTIUM. Neuro-Oncology, 2020, 22, iii420-iii421.	1.2	9
42	Mass cytometry detects H3.3K27M-specific vaccine responses in diffuse midline glioma. Journal of Clinical Investigation, 2020, 130, 6325-6337.	8.2	70
43	Phase I study of vemurafenib in children with recurrent or progressive BRAFV600E mutant brain tumors: Pacific Pediatric Neuro-Oncology Consortium study (PNOC-002). Oncotarget, 2020, 11, 1942-1952.	1.8	45
44	EPCT-01. PHASE I STUDY OF DAY101 (TAK580) IN CHILDREN AND YOUNG ADULTS WITH RADIOGRAPHICALLY RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMA (LGG). Neuro-Oncology, 2020, 22, iii304-iii304.	1.2	4
45	MODL-26. CHILDRENâ€™S BRAIN TUMOR NETWORK: ACCELERATING RESEARCH THROUGH COLLABORATION AND OPEN-SCIENCE. Neuro-Oncology, 2020, 22, iii416-iii416.	1.2	0
46	GCT-23. MULTI-INSTITUTIONAL ANALYSIS OF TREATMENT MODALITIES IN BASAL GANGLIA AND THALAMIC GERMINOMA. Neuro-Oncology, 2020, 22, iii332-iii332.	1.2	0
47	Introduction. Pediatric brain tumor. Neurosurgical Focus, 2020, 48, E1.	2.3	1
48	The genetic landscape of anaplastic pleomorphic xanthoastrocytoma. Brain Pathology, 2019, 29, 85-96.	4.1	88
49	Comparative Tumor RNA Sequencing Analysis for Difficult-to-Treat Pediatric and Young Adult Patients With Cancer. JAMA Network Open, 2019, 2, e1913968.	5.9	38
50	Diffusion Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3-K27M Mutation Using Apparent Diffusion Coefficient Histogram Analysis. American Journal of Neuroradiology, 2019, 40, 1804-1810.	2.4	27
51	Pediatric and adult H3 K27M-mutant diffuse midline glioma treated with the selective DRD2 antagonist ONC201. Journal of Neuro-Oncology, 2019, 145, 97-105.	2.9	125
52	Brainstem Injury in Pediatric Patients Receiving Posterior Fossa Photon Radiation. International Journal of Radiation Oncology Biology Physics, 2019, 105, 1034-1042.	0.8	16
53	Recurrent non-canonical histone H3 mutations in spinal cord diffuse gliomas. Acta Neuropathologica, 2019, 138, 877-881.	7.7	21
54	A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma. Journal of Neuro-Oncology, 2019, 144, 445-452.	2.9	17

#	Article	IF	Citations
55	Detection and Monitoring of Tumor Associated Circulating DNA in Patient Biofluids. Journal of Visualized Experiments, 2019, , .	0.3	5
56	Oncolytic Measles Virotherapy and Opposition to Measles Vaccination. Mayo Clinic Proceedings, 2019, 94, 1834-1839.	3.0	9
57	HGG-15. SUCCESSFUL TREATMENT OF AN NTRK-FUSION POSITIVE INFANTILE GLIOBLASTOMA WITH LAROTRECTINIB, A TARGETED TRK INHIBITOR. Neuro-Oncology, 2019, 21, ii89-ii90.	1.2	4
58	HGG-24. COMPREHENSIVE GENOMIC ANALYSIS OF PEDIATRIC GLIOMAS UNCOVERS NOVEL MUTATIONS IN HISTONE-ENCODING GENES. Neuro-Oncology, 2019, 21, ii91-ii92.	1.2	0
59	IMMU-18. TARGETING H3.3 K27M MUTATION AS A SHARED NEOANTIGEN IN HLA-A*0201+ PATIENTS WITH DIFFUSE MIDLINE GLIOMAS â€“ DEVELOPMENT OF A NOVEL MASS CYTOMETRY-BASED MONITORING OF VACCINE-REACTIVE, EPITOPE-SPECIFIC CD8+ T CELL RESPONSES. Neuro-Oncology, 2019, 21, ii96-ii96.	1.2	1
60	GENE-20. MULTI-GENE MUTATION PROFILING OF PEDIATRIC MIDLINE GLIOMAS USING PATIENT LIQUID BIOPSY. Neuro-Oncology, 2019, 21, ii85-ii85.	1.2	0
61	A pilot precision medicine trial for children with diffuse intrinsic pontine gliomaâ€”PNOC003: A report from the Pacific Pediatric Neuroâ€Oncology Consortium. International Journal of Cancer, 2019, 145, 1889-1901.	5.1	84
62	Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro-Oncology, 2019, 21, 968-980.	1.2	52
63	The genetic landscape of gliomas arising after therapeutic radiation. Acta Neuropathologica, 2019, 137, 139-150.	7.7	57
64	Deep sequencing of WNT-activated medulloblastomas reveals secondary SHH pathway activation. Acta Neuropathologica, 2018, 135, 635-638.	7.7	17
65	Prospective feasibility and safety assessment of surgical biopsy for patients with newly diagnosed diffuse intrinsic pontine glioma. Neuro-Oncology, 2018, 20, 1547-1555.	1.2	82
66	Large Vessel Arteriopathy After Cranial Radiation Therapy in Pediatric Brain Tumor Survivors. Journal of Child Neurology, 2018, 33, 359-366.	1.4	27
67	New therapeutic approaches for brainstem tumors: a comparison of delivery routes using nanoliposomal irinotecan in an animal model. Journal of Neuro-Oncology, 2018, 136, 475-484.	2.9	22
68	Novel and shared neoantigen derived from histone 3 variant H3.3K27M mutation for glioma T cell therapy. Journal of Experimental Medicine, 2018, 215, 141-157.	8.5	186
69	Survival outcomes in pediatric recurrent high-grade glioma: results of a 20-year systematic review and meta-analysis. Journal of Neuro-Oncology, 2018, 137, 103-110.	2.9	48
70	Pediatric low-grade gliomas: next biologically driven steps. Neuro-Oncology, 2018, 20, 160-173.	1.2	116
71	PDCT-04. PHASE 1 TRIAL OF WEE1 KINASE INHIBITOR AZD1775 COMBINED WITH RADIATION THERAPY FOR CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA: A REPORT FROM THE CHILDRENâ€™S ONCOLOGY GROUP PHASE 1 PILOT CONSORTIUM (ADVL1217). Neuro-Oncology, 2018, 20, vi201-vi201.	1.2	3
72	TBIO-29. PedcBioPortal, A CANCER DATA VISUALIZATION TOOL FOR INTEGRATIVE PEDIATRIC CANCER ANALYSES. Neuro-Oncology, 2018, 20, i186-i186.	1.2	0

#	Article	IF	Citations
73	NIMG-67. CLINICAL APPLICATIONS OF QUANTITATIVE THREE-DIMENSIONAL MRI ANALYSIS FOR PEDIATRIC EMBRYONAL BRAIN TUMORS. Neuro-Oncology, 2018, 20, vi191-vi191.	1.2	0
74	DIPG-56. PRECLINICAL STUDIES OF DIANHYDROGALACTITOL (VAL-083) IN DIPG, AS SINGLE AGENT OR AS A COMBINATION WITH RADIATION OR AZD1775. Neuro-Oncology, 2018, 20, i60-i60.	1.2	0
75	HGG-38. DEVELOPMENT AND COMPREHENSIVE CHARACTERIZATION AND UTILIZATION OF PRECLINICAL MODELS OF PEDIATRIC HIGH GRADE GLIOMAS. Neuro-Oncology, 2018, 20, i97-i97.	1.2	0
76	TBIO-27. GABRIELLA MILLER KIDS FIRST DATA RESOURCE CENTER ADVANCING GENETIC RESEARCH IN CHILDHOOD CANCER AND STRUCTURAL BIRTH DEFECTS THROUGH LARGE SCALE INTEGRATED DATA-DRIVEN DISCOVERY AND CLOUD-BASED PLATFORMS FOR COLLABORATIVE ANALYSIS. Neuro-Oncology, 2018, 20, i186-i186.	1.2	0
77	TBIO-28. DISEASEXPRESS, A CANCER DATA ANALYTICS AND VISUALIZATION TOOL FOR IDENTIFYING IMMUNOTHERAPEUTIC TARGETS IN PEDIATRIC BRAIN TUMORS AND OTHER CANCERS. Neuro-Oncology, 2018, 20, i186-i186.	1.2	0
78	DDIS-16. ONC201 IN COMBINATION WITH RADIATION EXHIBITS SYNERGISTIC EFFICACY IN HIGH GRADE GLIOMAS AND OTHER ADVANCED CANCERS. Neuro-Oncology, 2018, 20, vi72-vi72.	1.2	1
79	RTHP-21. CHARACTERIZATION OF RADIATION THERAPY EFFECTS ON CEREBRAL VASCULATURE IN PEDIATRIC BRAIN TUMOR SURVIVORS. Neuro-Oncology, 2018, 20, vi229-vi229.	1.2	2
80	EXTH-09. DIANHYDROGALACTITOL (VAL-083) HAS THE POTENTIAL TO OVERCOME MAJOR CHALLENGES IN THE TREATMENT OF DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG). Neuro-Oncology, 2018, 20, vi86-vi87.	1.2	0
81	Early detection of recurrent medulloblastoma: the critical role of diffusion-weighted imaging. Neuro-Oncology Practice, 2018, 5, 234-240.	1.6	10
82	Clinically Relevant and Minimally Invasive Tumor Surveillance of Pediatric Diffuse Midline Gliomas Using Patient-Derived Liquid Biopsy. Clinical Cancer Research, 2018, 24, 5850-5859.	7.0	118
83	Reirradiation and PD-1 inhibition with nivolumab for the treatment of recurrent diffuse intrinsic pontine glioma: a single-institution experience. Journal of Neuro-Oncology, 2018, 140, 629-638.	2.9	44
84	Abnormal Morphology of Select Cortical and Subcortical Regions in Neurofibromatosis Type 1. Radiology, 2018, 289, 499-508.	7.3	12
85	Dual HDAC and PI3K Inhibition Abrogates NFÎºB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas. Cancer Research, 2018, 78, 4007-4021.	0.9	60
86	The genetic landscape of ganglioglioma. Acta Neuropathologica Communications, 2018, 6, 47.	5.2	130
87	DIPG-76. PNOC-003: PRECISION MEDICINE TRIAL FOR CHILDREN WITH DIFFUSES INTRINSIC PONTINE GLIOMA: PRELIMINARY EXPERIENCE WITH MULTI-AGENT PERSONALIZED THERAPY RECOMMENDATIONS. Neuro-Oncology, 2018, 20, i64-i64.	1.2	2
88	Clinical Applications of Quantitative 3-Dimensional MRI Analysis for Pediatric Embryonal Brain Tumors. International Journal of Radiation Oncology Biology Physics, 2018, 102, 744-756.	0.8	10
89	Pediatric low-grade gliomas: implications of the biologic era. Neuro-Oncology, 2017, 19, now209.	1.2	73
90	Targeted next-generation sequencing of pediatric neuro-oncology patients improves diagnosis, identifies pathogenic germline mutations, and directs targeted therapy. Neuro-Oncology, 2017, 19, now254.	1.2	155

#	Article	IF	Citations
91	Pediatric high-grade glioma: biologically and clinically in need of new thinking. Neuro-Oncology, 2017, 19, now101.	1.2	217
92	Evaluation of Preâ€“Hematopoietic Cell Transplantation (HCT) Brain MRI and Neurologic Complications of Pediatric Patients Undergoing HCT for Hematologic Malignancies. Journal of Pediatric Oncology Nursing, 2017, 34, 65-73.	1.5	0
93	Imaging Characteristics of Pediatric Diffuse Midline Gliomas with Histone H3 K27M Mutation. American Journal of Neuroradiology, 2017, 38, 795-800.	2.4	132
94	Pediatric high-grade glioma: current molecular landscape and therapeutic approaches. Journal of Neuro-Oncology, 2017, 134, 541-549.	2.9	109
95	Survival after chemotherapy and stem cell transplant followed by delayed craniospinal irradiation is comparable to upfront craniospinal irradiation in pediatric embryonal brain tumor patients. Journal of Neuro-Oncology, 2017, 131, 359-368.	2.9	13
96	GENE-43. LIQUID BIOPSY FOR MONITORING OF TUMOR RESPONSE IN CHILDREN WITH DIFFUSE MIDLINE GLIOMA. Neuro-Oncology, 2017, 19, vi101-vi102.	1.2	0
97	PDCT-19. AÂSAFETY STUDY OF VEMURAFENIB, AN ORAL INHIBITOR OF BRAFV600E, IN CHILDREN WITH RECURRENT/REFRACTORY BRAFV600E MUTANT BRAIN TUMORS: PNOC-002. Neuro-Oncology, 2017, 19, vi188-vi188.	1.2	6
98	Case-based review: pediatric medulloblastoma. Neuro-Oncology Practice, 2017, 4, 138-150.	1.6	22
99	Therapeutic and Prognostic Implications of BRAF V600E in Pediatric Low-Grade Gliomas. Journal of Clinical Oncology, 2017, 35, 2934-2941.	1.6	232
100	Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTOR signaling pathways. Oncotarget, 2017, 8, 84697-84713.	1.8	38
101	RO-02CEREBRAL MICROBLEEDS ARE ASSOCIATED WITH WORSE EXECUTIVE FUNCTION IN PEDIATRIC BRAIN TUMOR SURVIVORS. Neuro-Oncology, 2016, 18, iii159.2-iii159.	1.2	25
102	IDH1 mutation can be present in diffuse astrocytomas and giant cell glioblastomas of young children under 10Âyears of age. Acta Neuropathologica, 2016, 132, 153-155.	7.7	20
103	Presence of cerebral microbleeds is associated with worse executive function in pediatric brain tumor survivors. Neuro-Oncology, 2016, 18, now163.	1.2	33
104	Clinical trials in pediatric neuro-oncology: what is missing and how we can improve. CNS Oncology, 2016, 5, 233-239.	3.0	9
105	Late Effects of Treatment of Pediatric Central Nervous System Tumors. Journal of Child Neurology, 2016, 31, 237-254.	1.4	81
106	Survival advantage combining a BRAF inhibitor and radiation in BRAF V600E-mutant glioma. Journal of Neuro-Oncology, 2016, 126, 385-393.	2.9	31
107	MYB-QKI rearrangements in angiocentric glioma drive tumorigenicity through a tripartite mechanism. Nature Genetics, 2016, 48, 273-282.	21.4	214
108	InactivatingMUTYHgermline mutations in pediatric patients with high-grade midline gliomas. Neuro-Oncology, 2016, 18, 752-753.	1.2	20

#	Article	IF	Citations
109	Clinical outcome and prognostic factors for central neurocytoma: twenty year institutional experience. Journal of Neuro-Oncology, 2016, 126, 193-200.	2.9	45
110	Rates and Characteristics of Radiographically Detected Intracerebral Cavernous Malformations After Cranial Radiation Therapy in Pediatric Cancer Patients. Journal of Child Neurology, 2015, 30, 842-849.	1.4	39
111	Recurrent stroke in childhood cancer survivors. Neurology, 2015, 85, 1056-1064.	1.1	41
112	EAG2 potassium channel with evolutionarily conserved function as a brain tumor target. Nature Neuroscience, 2015, 18, 1236-1246.	14.8	74
113	WEE1 Kinase As a Target for Cancer Therapy. Journal of Clinical Oncology, 2015, 33, 3485-3487.	1.6	46
114	Targeting Wee1 for the treatment of pediatric high-grade gliomas. Neuro-Oncology, 2014, 16, 352-360.	1.2	102
115	Pharmacologic inhibition of histone demethylation as a therapy for pediatric brainstem glioma. Nature Medicine, 2014, 20, 1394-1396.	30.7	411
116	Feasibility, safety, and indications for surgical biopsy of intrinsic brainstem tumors in children. Child's Nervous System, 2013, 29, 1313-1319.	1.1	62
117	Risk of First and Recurrent Stroke in Childhood Cancer Survivors Treated With Cranial and Cervical Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2013, 86, 643-648.	0.8	52
118	Radiation, Atherosclerotic Risk Factors, and Stroke Risk in Survivors of Pediatric Cancer: A Report From the Childhood Cancer Survivor Study. International Journal of Radiation Oncology Biology Physics, 2013, 86, 649-655.	0.8	124
119	The histone H3.3K27M mutation in pediatric glioma reprograms H3K27 methylation and gene expression. Genes and Development, 2013, 27, 985-990.	5.9	570
120	Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma. Anticancer Research, 2013, 33, 755-62.	1.1	20
121	PTEN promoter methylation and activation of the PI3K/Akt/mTOR pathway in pediatric gliomas and influence on clinical outcome. Neuro-Oncology, 2012, 14, 1146-1152.	1.2	85
122	Cooperation of the HDAC inhibitor vorinostat and radiation in metastatic neuroblastoma: Efficacy and underlying mechanisms. Cancer Letters, 2011, 306, 223-229.	7.2	66
123	Neuroblastoma: Biology and staging. Current Oncology Reports, 2009, 11, 431-438.	4.0	88
124	Pediatric Pineoblastoma: A pooled outcome study of North American and Australian therapeutic data. Neuro-Oncology Advances, 0, , .	0.7	6
125	An Integrated Analysis of Clinical, Genomic, and Imaging Features Reveals Predictors of Neurocognitive Outcomes in a Longitudinal Cohort of Pediatric Cancer Survivors, Enriched with CNS Tumors (Rad ART Pro). Frontiers in Oncology, 0, 12, .	2.8	2